Rocket Pharmaceuticals Welcomes New CFO Aaron Ondrey

Rocket Pharmaceuticals (RCKT) has shared an announcement.

Rocket Pharmaceuticals, Inc. has appointed Aaron Ondrey as their new Chief Financial Officer and Principal Financial Officer, bringing his extensive expertise from prior roles at high-profile biotech firms like Mirati Therapeutics and Arena Pharmaceuticals. Ondrey’s financial acumen is backed by his Bachelor’s in Business Administration and Finance, and his compensation includes a $485,000 base salary, potential bonuses, and $2.5 million in equity. His agreement outlines severance benefits and additional terms, underscoring the strategic move by Rocket Pharmaceuticals to strengthen their executive team with a seasoned finance professional.

For a thorough assessment of RCKT stock, go to TipRanks’ Stock Analysis page.